<unk>  arises from  B cells, that are normally involved in the process of human immunoglobulins production. However, the exact B cell maturation stage involved in the development of<unk>  is still unclear. The most common gene involved in the pathogenesis of<unk>  is a BRAF V600E mutation. On microscopic histopathological analysis, characteristic findings of<unk>  include small cells with "fried egg"-like appearance, well-demarcated thread-like cytoplasmic extensions, and a clear cytoplasm.<unk>  is found to approximately comprise 2% of all leukemias in the United States. The incidence of<unk>  is approximately 3.2 per 1,000,000 individuals in the United States. The incidence of<unk>  increases with age; the median age at diagnosis is 58 years. Males are more commonly affected with<unk>  than females. The male to female ratio is approximately 4 to 1. Studies have proposed a number of risk factors for the development of<unk>  such as certain chemicals exposure, radiation exposure, and sawdust exposure. Symptoms of<unk>  include fever, night sweats, and weight loss.  Physical examination of patients with<unk>  is usually remarkable for pallor, petechiae, and splenomegaly. Laboratory findings consistent with the diagnosis of<unk>  include abnormal complete blood count, immunohistochemistry, and flow cytometry. The presence of<unk>  cells with thread-like cytoplasmic extensions on blood smear is a key diagnostic feature among patients with<unk> . There are no curative treatments for<unk> . The mainstay of therapy for<unk>  patients is chemotherapy. Pharmacological agents used for the treatment of<unk>  patients include cladribine, pentostatin, rituximab, and vemurafenib.
Hairy cell leukemia
Adult T-cell leukemia
Prolymphocytic leukemia
B-cell leukemia
T-cell leukemia
Leukemoid reaction
T-cell prolymphocytic leukemia electrocardiogram
Lymphoid leukemia